Grail Inc
NASDAQ:GRAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lightspeed Commerce Inc
TSX:LSPD
|
CA |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Grail Inc
NASDAQ:GRAL
|
2B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Grail Inc
Glance View
Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Grail Inc is 48.5%, which is above its 3-year median of 43.9%.
Over the last 2 years, Grail Inc’s Gross Margin has increased from 41.1% to 48.5%. During this period, it reached a low of 41.1% on Dec 1, 2023 and a high of 48.5% on Jan 31, 2026.
